Electrochemiluminescence biosensor for specific detection of pancreatic ductal carcinoma through dual targeting of MUC1 and miRNA-196a

• Published in: Biosensors & bioelectronics 2024-06, Vol.254, p.116241-116241, Article 116241
• Main Authors: Chen, Yuxuan, Ye, Zhuoxin, Ma, Mo, Yang, Jukun, Liu, Ruiyan, Zhang, Yan, Ma, Pinyi, Song, Daqian
• Format: Article
• Language: English
• Subjects: Biomarkers; Biosensing Techniques; Biosensor; Carcinoma, Pancreatic Ductal - diagnosis; Carcinoma, Pancreatic Ductal - genetics; Carcinoma, Pancreatic Ductal - pathology; Dual targeting; Electrochemiluminescence; Humans; microRNA-196a; MicroRNAs - genetics; MUC1; Mucin-1; Pancreatic ductal adenocarcinoma; Pancreatic Neoplasms - diagnosis; Pancreatic Neoplasms - genetics
• ISSN: 0956-5663; 1873-4235
• DOI: 10.1016/j.bios.2024.116241

Pancreatic ductal adenocarcinoma (PDAC) poses significant diagnostic challenges due to its asymptomatic nature in its early stages, low specificity of conventional in vitro assays, and limited efficacy of surgical interventions. However, clinical specificity of the current serum biomarkers is suboptimal, leading to diagnostic inaccuracies and oversights. Therefore, this study introduced a novel dual-target electrochemiluminescence (ECL) biosensor to address these critical issues. The ECL biosensor synergistically employs the serum biomarker MUC1 and microRNA-196a to detect early-stage PDAC precisely. While MUC1 is a differential marker between normal and cancerous pancreatic cells, its standalone diagnostic performance is limited. However, integrating miRNA-196a as a complementary marker substantially enhances the specificity of the assay. This biosensor exhibits distinct ECL signal modulation—"on-off” in the presence of MUC1 and “off-on” upon concurrent detection of MUC1 and miRNA-196a. The biosensor achieves remarkably low limits of detection (LODs) at 0.63 fg mL−1 and 4.57 aM for MUC1 and miRNA-196a, respectively. Thus, it facilitates the real-time differentiation between human normal pancreatic (hTERT-HPNE) and pancreatic cancer (PANC-1) cells in authentic biological matrices. This innovative approach heralds a significant advancement in the early and specific detection of PDAC, offering promising prospects for clinical translation and the broader landscape of cancer diagnostics.